Sana Biotechnology (SANA) Total Non-Current Liabilities (2020 - 2026)

Sana Biotechnology's Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $244.5 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 7.76% year-over-year to $244.5 million; the TTM figure through Mar 2026 stood at $244.5 million (up 7.76% YoY), while the FY2025 annual figure was $172.5 million, down 28.32% from the prior year.
• Total Non-Current Liabilities came in at $244.5 million for Q1 2026 at Sana Biotechnology, up from $172.5 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $271.7 million in Q2 2024 to a low of $162.4 million in Q3 2023.
• A 5-year average of $220.6 million and a median of $233.6 million in 2022 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities surged 59.73% in 2024 and slumped 36.26% in 2025, its largest moves.
• Sana Biotechnology's Total Non-Current Liabilities stood at $228.4 million in 2022, then declined by 26.35% to $168.2 million in 2023, then soared by 43.07% to $240.6 million in 2024, then fell by 28.32% to $172.5 million in 2025, then soared by 41.78% to $244.5 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $244.5 million, $172.5 million, and $176.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison